Models of risk determination of cancer-associated thromboses


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Thromboembolic diseases occupy a leading position in the structure of general mortality of the population, and in patients with malignant neoplasms they significantly increase the risk of adverse events. Current article presents the main models for predicting thromboembolic complications in patients with cancer. As follows from the represented data, in a number of cases of pulmonary embolism patients it is possible to prevent the development of a life-threatening complication at the stage of hypercoagulable syndrome. When assessing the risk of thromboembolic complications in patients with malignant neoplasms, a convenient and highly sensitive scale for assessing the risk of thromboembolic complications is required.

Full Text

Restricted Access

About the authors

Larisa V. Tarasova

I.N. Ulyanov Chuvash State University; Surgut State University

MD, head of the Department of faculty and hospital therapy

Olga V. Dimitrieva

I.N. Ulyanov Chuvash State University; Republican Cardiological Dispensary of the Ministry of Healthcare of the Chuvash Republic

postgraduate student of the Department of faculty and hospital therapy

Igor Yu. Dolgov

I.N. Ulyanov Chuvash State University; Republican Clinical Oncological Dispensary of the Ministry of Healthcare of Chuvashia

MD, professor of the Department of general surgery and oncology of the faculty of medicine

Aziza A. Elmurzayeva

Surgut State University

postgraduate student of the Department of internal diseases of the medical institute

References

  1. Gary T., Belaj K., Steidl K.et al. Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact on short-term survival. Br J. Cancer. 2012; 107(8): 1244-48. doi: 10.1038/bjc.2012.401.
  2. Ahern T.P., Horvath-Puho E., Spindler K.G. et al. Colorectal cancer comorbidity, and risk of venous thromboembolism: assessment of biological interactions in a Danish nationwide cohort. Br J. Cancer. 2016; 114(1): 96-102. doi: 10.1038/bjc.2015.406.
  3. Лобастов К.В., Дементьева Г.И., Лаберко Л.А. Современные представления об этиологии и патогенезе венозного тромбоза: переосмысление триады Вирхова. Флебология. 2019; 3: 227-235. doi: https://doi.org/10.17116/flebo201913031227.
  4. Khalil J., Bensaid B., Elkacemi H. et al. Venous thromboembolism in cancer patients: an underestimated major health problem. World J. Surg Oncol. 2015; 13: 204. doi: 10.1186/s12957-015-0592-8.
  5. Riva N., Bellesini M., Di Minno M.N. et al. Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study. Thromb Haemost. 2014; 112(3): 511-21. doi: 10.1160/TH14-01-0081.
  6. Streiff M.B., Holmstrom B., Ashrani A. et al. Cancer-associated venous thromboembolic disease, version 1. 2015. J. Natl Compr Canc Netw. 2015; 13(9): 1079-95. doi: 10.6004/jnccn.2015.0133.
  7. Tran B.H., Nguyen T.J., Hwang B.H. et al. Risk factors associated with venous thromboembolism in 49,028 mastectomy patients. Breast. 2013; 22(4): 444-48. doi: 10.1016/j.breast.2013.04.018.
  8. Клинические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных. Общероссийский союз общественных объединений «Ассоциация онкологов России». М.: 2014. Доступ: http://www.oncology.ru/association/clinical-guidelines/2014/51.pdf (дата обращения - 01.09.2021).
  9. Watson H.G., Keeling D.M., Laffan M. et al.; British Committee for Standards in Haematology. Guideline on aspects of cancer-related venous thrombosis. Br J. Haematol. 2015; 170(5): 640-48. doi: 10.1111/bjh.13556.
  10. Бокерия Л.А., Затевахин И.И., Кириенко А.И. с соавт. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2015; 4-2: 1-52.
  11. Федоткина Ю.А., Панченко Е.П. Профилактика венозных тромбоэмболических осложнений у пациентов с активным онкологическим заболеванием, получающих медикаментозную противораковую химиотерапию в амбулаторных условиях. Роль апиксабана. doi: https://doi.org/10.21518/2307-1109-2019-2-46-54.
  12. Konigsbrugge O., Pabinger I., Ay C. Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). Thromb Res. 2014; 133(Suppl 2): S39-43. doi: 10.1016/S0049-3848(14)50007-2.
  13. Chew H.K., Wun T., Harvey D. et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166(4): 458-64. doi: 10.1001/archinte.166.4.458.
  14. Khorana A.A., Connolly G.C. Assessing risk of venous thromboembolism in the patient with cancer. J. Clin Oncol. 2009; 27(29): 4839-47. doi: 10.1200/JCC.2009.22.3271.
  15. Blom J.W., Vanderschoot J.P.M., Oostindier M.J. et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J. Thromb Haemost. 2006; 4(3): 529-35. doi: 10.1111/j.1538-7836.2006.01804.x.
  16. Farge D., Debourdeau P., Beckers M. et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J. Thromb Haemost. 2013; 11(1): 56-70. doi: 10.1111/jth.12070.
  17. Ay C., Dunkler D., Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010; 116(24): 5377-82. doi: 10.1182/blood-2010-02-270116.
  18. Verso M., Agnelli G., Barni S. et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012; 7(3): 291-92. doi: 10.1007/s11739-012-0784-y.
  19. Pelzer U., Sinn M., Stieler J., Riess H. [Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?]. [Article in German]. Dtsch Med Wochenschr. 2013; 138(41): 2084-88. doi: 10.1055/s-0033-1349608.
  20. van Es N., Di Nisio M., Cesarman G. et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017; 102(9): 1494-501. doi: 10.3324/haematol.2017.169060.
  21. Gerotziafas G.T., Taher A., Abdel-Razeq H. et al.; COMPASS-CAT Working Group. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: The prospective COMPASS-Cancer-Associated Thrombosis study. Oncologist. 2017; 22(10): 1222-31. doi: 10.1634/theoncologist.2016-0414.
  22. Cella C.A., Di Minno G., Carlomagno C. et al. Preventing venous thromboembolism in ambulatory cancer patients: The ONKOTEV study. Oncologist. 2017; 22(5): 601-08. doi: 10.1634/theoncologist.2016-0246.
  23. Munoz Martin A.J., Ortega I., Font C. et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J. Cancer. 2018; 118(8): 1056-61. doi: 10.1038/s41416-018-0027-8.
  24. Pabinger I., van Es N., Heinze G. et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol. 2018; 5(7): e289-e298. doi: 10.1016/ S2352-3026(18)30063-2.
  25. Syrigos K., Grapsa D., Sangare R. et al. Prospective assessment of clinical risk factors and biomarkers of hypercoagulability for the identification of patients with lung adenocarcinoma at risk for cancer-associated thrombosis: The observational ROADMAP-CAT study. Oncologist. 2018; 23(11): 1372-81. doi: 10.1634/theoncologist.2017-0530.
  26. Antic D., Milic N., Nikolovski S. et al. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. Am J. Hematol. 2016; 91(10): 1014-19. doi: 10.1002/ajh.24466.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies